Services Case Types About Insights Inquire
IME · Psychiatric & Addiction Medicine Consulting

Causation clarity
before you commit
to strategy.

I help attorneys and insurers determine whether psychiatric and substance-related claims are clinically defensible — before expert retention, litigation strategy, or reserve decisions are locked.

Independent Medical Examiner
IME — Psychiatric & Addiction Medicine
Board Certification
Psychiatry — American Board of Psychiatry & Neurology (ABPN)
Board Certification
Addiction Medicine — American Board of Preventive Medicine (ABPM)
Advanced Training
Psychedelic-Assisted Therapies & Research — California Institute of Integral Studies (CIIS)
Advanced Training
Master Psychopharmacology Program — Neuroscience Education Institute (NEI)
Active Status
California Qualified Medical Evaluator (QME) · Licensed CA & TX
The Core Question

Not whether a diagnosis exists.
Whether it was caused.

A positive drug test does not establish impairment. A PTSD diagnosis does not establish your client caused it. A treating provider's report does not establish the clinical record supports the claimed severity.

The question that determines case value is causation — whether the substance, the event, or the condition credibly produced the injury being claimed, at the severity being claimed, for the duration being claimed.

Most evaluations answer that question too late — after expert retention costs have accumulated and litigation strategy is already committed. I answer it early, when the answer still changes your decisions.

"I work primarily as a consulting expert — early triage, record review, causation analysis. I testify selectively on matters squarely within my subspecialty."

For Defense Counsel

Know whether the opposing psychiatric damages theory holds up before you build a litigation strategy around assumptions. One early review changes your mediation position entirely.

For Coverage Counsel & Insurers

Reserve accuracy on psychiatric injury claims is notoriously difficult. A focused clinical triage before strategy locks protects against both over-reserving and under-reserving seven-figure exposure.

For Plaintiff Counsel

Before committing contingency hours to a psychiatric injury case, know whether the damages theory survives what defense will throw at it — and where the clinical record will be attacked.

For TPAs & Risk Managers

Early clinical triage on GL and EPLI psychiatric claims drives better reserve decisions and earlier resolution — before the claim matures into full litigation.

How I Work

Focused engagements.
Clean deliverables.

Every engagement is structured around a specific clinical question and a defined deliverable. Independent Medical Examinations (IME), record reviews, and causation analyses are conducted with no open-ended retainers, no scope drift, no informal opinions that create undocumented exposure.

01

Case Screening

Focused intake review to determine scope fit and identify the core clinical question. Completed within 48 hours of receiving the case summary. $500 flat, applied to engagement if retained.

02

Record Review & Causation Analysis

Comprehensive review of psychiatric, medical, pharmacy, and relevant records. Written memo addressing causation, severity credibility, and clinical risk factors. Tiered flat fees based on record volume.

03

Substance Impairment Analysis

Specialized assessment of whether a substance — alcohol, cannabis, prescription medication, or emerging compounds including psychedelics — produced actual impairment at the time of the incident. Not just presence. Impairment.

04

Strategic Consultation

Post-memo strategy calls, deposition preparation for treating providers, or follow-up analysis as the matter develops. Billed hourly at $500/hr, one-hour minimum.

05

Expert Testimony

Available selectively on matters squarely within the subspecialty of psychiatric and substance-related causation. Deposition and trial testimony following full record review and written report.

06

Retainer Arrangements

For insurers and TPAs with recurring psychiatric claim volume. Monthly retainer covering defined intake screenings and discounted review rates. Priority access and consistent early triage across your book.

Why This Practice

A credential combination
the market cannot replicate.

Dual Board Certification

Board-certified in both Psychiatry (ABPN) and Addiction Medicine (ABPM) — a combination held by very few forensic consultants. Most evaluators assess psychiatric injury or substance use. This practice assesses both simultaneously, including their interaction.

Psychedelic Medicine Expertise

Completed a year-long program in Psychedelic-Assisted Therapies and Research at CIIS — among the only physicians qualified to assess causation and impairment involving ketamine, psilocybin, MDMA, and emerging compounds in a forensic context.

Master Psychopharmacology

Advanced psychopharmacology training through NEI provides depth of pharmacological analysis directly relevant to impairment duration, drug interaction, and medication causation — beyond standard psychiatric evaluation.

Active California QME Status

Current Qualified Medical Evaluator in California with extensive deposition experience. Familiarity with how California courts and carriers evaluate psychiatric and substance-related evidence in contested matters.

The Impairment Question

The central question in substance-related matters is not whether a compound was present — it is whether actual impairment existed at the time of the incident, and for how long. That question requires expertise most evaluators do not have. It is the core of this practice.

Non-Testifying by Default

Consulting engagements are protected by attorney work product. No testimony agenda influences the analysis. The opinion you receive is honest — not shaped by what would survive cross-examination. That intellectual freedom produces better analysis.

Matter Types

Where this practice
delivers the most value.

Primary Focus

Large-Loss Personal Injury

Catastrophic injury with psychiatric overlay — TBI plus psych, chronic pain plus depression, trauma claims where causation and severity are disputed.

Primary Focus

Employment / EPLI

Hostile work environment, harassment, disability discrimination claims where psychiatric causation and damages severity are central to settlement value.

Primary Focus

Substance Causation Matters

Any matter where alcohol, cannabis, prescription medications, or emerging compounds are relevant to liability, impairment at time of incident, or claimed injury causation.

Secondary Focus

Coverage Disputes

Psychiatric injury claims where the clinical evidence bears on whether policy coverage is triggered or excluded. Reserve accuracy before strategy locks.

Secondary Focus

Medical Malpractice Defense

Matters where psychiatric damages are a component of claimed injury. Causation and severity analysis before expert retention.

Secondary Focus

Psychedelic Medicine Claims

Ketamine clinic liability, psilocybin therapy adverse events, MDMA-related injury claims — an emerging area with very limited qualified evaluators available nationally.

About

The physician
behind the practice.

Fayaz Ibrahim, MD
Fayaz Ibrahim, MD
Psychiatrist & Addiction Medicine Specialist
  • Board-Certified, Psychiatry — ABPN (2011, 2022)
  • Board-Certified, Addiction Medicine — ABPM (2023)
  • Psychedelic-Assisted Therapies & Research — CIIS (2024–2025)
  • Master Psychopharmacology Program — NEI (2016)
  • Psychiatry Residency — SUNY Downstate Medical Center
  • Center for Movement Disorders — Columbia University Neurology
  • Active California Qualified Medical Evaluator (QME)
  • Licensed: California & Texas

Dr. Fayaz Ibrahim is a double board-certified psychiatrist and addiction medicine specialist with over fifteen years of forensic experience. He completed his psychiatry residency at SUNY Downstate Medical Center with a rotation at the Center for Movement Disorders, Columbia University Neurology — establishing a clinical foundation that spans both psychiatric and neurological dimensions of injury and impairment.

His forensic practice has focused on the intersection of psychiatric diagnosis, substance use, and causation — specifically the questions that determine case value: whether an event, a substance, or a pre-existing condition credibly caused the claimed injury, at the claimed severity, for the claimed duration.

As an active California Qualified Medical Evaluator with extensive deposition experience, Dr. Ibrahim's dual board certification combined with a Master Psychopharmacology credential from the Neuroscience Education Institute allows him to assess the full spectrum of substance-related causation questions with a depth of clinical and pharmacological expertise that generalist evaluators cannot match.

Recognizing the rapid emergence of psychedelic compounds in both clinical and legal contexts, Dr. Ibrahim completed a year-long program in Psychedelic-Assisted Therapies and Research at the California Institute of Integral Studies. He is among a very small number of physicians nationally qualified to assess causation and impairment involving these compounds in a forensic context.

Dr. Ibrahim has held academic appointments including Adjunct Assistant Professor at A.T. Still University School of Osteopathic Medicine and Vice-Chair of Psychiatry at KDHCD–UC Irvine School of Medicine. His peer-reviewed publications span geriatric psychiatry, psychopharmacology, and complex neuropsychiatric presentations.

Selected Publications

Psychosis and Capgras' Delusions in a Patient Diagnosed with Cogan's Syndrome
Clinical Case Reports Review, 2015 · Raese J, Ibrahim F
Management of Agitation Following Aneurysmal Subarachnoid Hemorrhage: Is There a Role for Beta-Blockers?
Case Reports in Psychiatry, 2012 · Ibrahim F, Viswanathan R
Successful Aging in Older Adults with Schizophrenia: Prevalence and Associated Factors
American Journal of Geriatric Psychiatry, 2010 · Ibrahim FA, Cohen CI, Ramirez PM
Primary Prevention in Geriatric Psychiatry
Annals of Clinical Psychiatry, 2010 · Madhusoodanan S, Ibrahim FA, Malik A
Anticipation of Serotonin Syndrome Due to Co-Administration of Linezolid with SSRI
The Resident's Journal, American Journal of Psychiatry, 2011 · Ibrahim F, Saunders R

Honors & Awards

AAGP–MIT National Research Award
American Association of Geriatric Psychiatry · 2009
AMA Physician Recognition Award
American Medical Association · 2010
Faculty of the Year
Kaweah Mental Health Hospital · 2012
Mental Health Service Award
Kaweah Health GME · 2012
Founding Faculty Member
Psychiatry Residency Program, Kaweah Health · 2013
Guest Speaker — Award Winners Research
AAGP Annual Conference, Honolulu · 2009
Insights

Thinking on the
questions that matter.

Forensic Psychiatry · Substance Causation

A Positive Drug Test Is Not Evidence of Impairment. Here Is Why That Distinction Determines Liability.

In substance-related injury litigation, one of the most consequential errors attorneys and adjusters make is treating toxicological presence as equivalent to functional impairment. They are not the same. The difference between them frequently determines whether a case settles at nuisance value or goes to seven figures — and courts are increasingly making this distinction explicit.

When a tox screen returns positive for cannabis, it establishes one thing: that the individual used cannabis at some point within the detection window — which, depending on the compound and the individual's pattern of use, may range from hours to weeks. It establishes nothing about whether the person was impaired at the time of the incident.

What the Courts Have Said

This is not merely a clinical argument — it is a legal one with real precedent. In Rose v. Berry Plastics Corp. (Oklahoma, 2019), a court reinstated workers' compensation benefits for a claimant who tested positive for marijuana after a workplace hand injury. The court explicitly rejected the inference that the mere presence of marijuana in a person's bloodstream means they were intoxicated at the time of the incident. The claimant had smoked marijuana the evening before, not on the day of the accident — and no supervisor observed any signs of impairment. Presence was established. Impairment was not. The distinction determined the outcome. (National Law Review)

A similar dynamic has played out in Texas. In Bituminous Fire & Marine Insurance v. Ricardo Ruel, a worker sustained electrical burns and tested positive for cocaine — and admitted to using it days before the accident. Yet the jury concluded he was not impaired at the time of the incident, and the appeals court affirmed. As the court noted, unlike alcohol, there is no statutory standard that establishes per se impairment from a controlled substance. The insurer's attempt to deny benefits on the basis of the positive test alone failed because toxicological presence and functional impairment are legally and clinically distinct. (Risk & Insurance)

Why Detection Windows Are Not Impairment Windows

THC produces acute cognitive and psychomotor impairment that typically peaks within 30–90 minutes of use and resolves substantially within 3–4 hours in most users. Yet THC metabolites remain detectable in urine for days in casual users and weeks in chronic users, long after any meaningful functional impairment has resolved.

This means a worker who tests positive after a workplace accident may have last used cannabis four days prior, with zero residual impairment at the time of the incident. Or they may have used hours before. The tox screen alone cannot answer which. Only a careful clinical analysis of use pattern, timing, route of administration, tolerance, and the specific cognitive demands of the task can begin to answer that question with defensible precision.

The Same Logic Applies Across Compounds

Alcohol metabolizes predictably — approximately 0.015% BAC per hour — making impairment reconstruction tractable when timing is established. Prescription opioids present different challenges: therapeutic use, tolerance, and the distinction between physical dependence and functional impairment require clinical judgment that toxicology alone cannot provide. Emerging compounds — including therapeutic psychedelics now appearing in workplace and injury contexts — present evaluation challenges that very few forensic practitioners have the training to address.

What This Means for Your Matter

Courts have made clear that a positive drug test is the beginning of the analysis, not the end. Whether you are defending against an impairment claim or building one, the critical question is not what the tox screen showed — it is whether actual functional impairment existed at the time that matters, and whether the clinical record and pharmacological evidence support that conclusion. That assessment, made early by a qualified physician, changes everything about how you approach the matter.

Inquire

Submit a matter
for consideration.

All inquiries are reviewed within one business day. A case screening ($500, applied to engagement if retained) determines whether the matter is within scope and identifies the core clinical question.

This practice does not accept all matters. Engagements are limited to psychiatric and substance-related causation questions within the defined scope of practice.

Email
Practice Focus
California (Primary) · Texas (Secondary)
Response Time
Within one business day